Application of novel targeting nanoparticles contrast agent combined with contrast‑enhanced computed tomography during screening for early‑phase gastric carcinoma

Zhang,Kaimin; Du,Xijian; Yu,Kaihu; Zhang,Kaiyu; Zhou,Yicheng

doi:10.3892/etm.2017.5388

Application of novel targeting nanoparticles contrast agent combined with contrast‑enhanced computed tomography during screening for early‑phase gastric carcinoma

Authors:
- Kaimin Zhang
- Xijian Du
- Kaihu Yu
- Kaiyu Zhang
- Yicheng Zhou
View Affiliations

Affiliations: Physical Examination Center, Xianning Central Hospital, Xianning, Hubei 437000, P.R. China, Department of Radiology, Xianning Central Hospital, Xianning, Hubei 437000, P.R. China, Department of Radiology, The First People's Hospital of Xianning City, Xianning, Hubei 437000, P.R. China, Department of Radiology, Tongji Medical College, Huazhong University of Science Tongji Hospital, Wuhan, Hubei 430030, P.R. China
Published online on: October 30, 2017 https://doi.org/10.3892/etm.2017.5388
Pages: 47-54
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer is one of the most common human tumors worldwide. The biggest bottleneck is a lack of advanced and sensitive protocols for the diagnosis of patients with early‑stage gastric cancer. Therefore, more sensitive methods of diagnosing gastric cancer are urgently required to improve survival rates. In this clinical study, contrast‑enhanced computed tomography (CECT) with targeting nanoparticles contrast agent (CECT‑TNCA) was used to diagnose early‑stage gastric cancer. The specific‑targeted tyrosine kinase inhibitors of gastric cancer, including platelet‑derived growth factor receptor‑β, Ret and Kit, were used as TNCAs. A total of 484 patients with suspected gastric cancer were voluntarily recruited to investigate the efficacy of CECT‑TNCA in the diagnosis of patients with early‑stage gastric cancer. Patients with suspected gastric cancer were subjected CT and CECT‑TNCA to detect whether gastric tumors existed. TNCA was orally administered before CT and CECT‑TNCA (20 min). Our diagnostic data revealed that CECT‑TNCA improved sensitivity and provided a new protocol to diagnose tumors in patients with suspected gastric cancer at the early stage. In addition, imaging using CECT‑TNCA enabled the visualization of tiny nodules in the gastric area. CECT‑TNCA diagnosed 182 patients with suspected gastric cancer as tumor‑free. CECT‑TNCA confirmed gastric cancer in 302 patients. Our novel diagnosis indicated significantly (P<0.01) differential signal enhancement in the gastric nodules via CECT‑TNCA compared with CT, suggesting higher accuracy and the accumulation of TNCA in tumor nodules in the stomach. Furthermore, survival rates of patients detected by early‑diagnosis of CECT‑TNCA were significantly higher than the mean five‑year survival (P<0.01). In conclusion, our investigations demonstrate that the sensibility and accuracy of CT is improved through combination with liposome‑encapsulated nanoparticle contrast agent for the diagnosis of early stage gastric cancer when compared with single CT detection. CECT‑TNCA improves the accuracy of CT and diagnostic confidence in assessing mural enhancement in patients with suspected gastric cancer.

View Figures

View References

1	Golpour S, Rafie N, Safavi SM and Miraghajani M: Dietary isoflavones and gastric cancer: A brief review of current studies. J Res Med Sci. 20:893–900. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hossain MM and Chen Z: Comments on ‘Application of an adaptive design to a randomized phase II selection trial in gastric cancer: A report of the study design’ by Satoshi Morita and Junichi Sakamoto. Pharmaceutical Statistics. Pharm Stat. 11:267–268. 2012. View Article : Google Scholar : PubMed/NCBI
3	Khayatzadeh S, Feizi A, Saneei P and Esmaillzadeh A: Vitamin D intake, serum Vitamin D levels, and risk of gastric cancer: A systematic review and meta-analysis. J Res Med Sci. 20:790–796. 2015. View Article : Google Scholar : PubMed/NCBI
4	Pimenta-Melo AR, Monteiro-Soares M, Libânio D and Dinis-Ribeiro M: Missing rate for gastric cancer during upper gastrointestinal endoscopy: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 28:1041–1049. 2016. View Article : Google Scholar : PubMed/NCBI
5	Veisani Y and Delpisheh A: Survival rate of gastric cancer in Iran; a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 9:78–86. 2016.PubMed/NCBI
6	Nakajima T, Inokuchi K, Hattori T, Inoue K, Taguchi T, Kondou T, Abe O, Kikuchi K, Tanabe T and Ogawa N: Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer-five-year survival rate. Gan To Kagaku Ryoho. 16:799–806. 1989.(Article in Japanese). PubMed/NCBI
7	Jung SA, Park YM, Hong SW, Moon JH, Shin JS, Lee HR, Ha SH, Lee DH, Kim JH, Kim SM, et al: Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells. J Biol Chem. 290:9974–9985. 2015. View Article : Google Scholar : PubMed/NCBI
8	Izawa M, Mori T, Satoh T, Teramachi K and Sairenji T: Identification of an alternative form of caspase-9 in human gastric cancer cell lines: A role of a caspase-9 variant in apoptosis resistance. Apoptosis. 4:321–325. 1999. View Article : Google Scholar : PubMed/NCBI
9	Moody SE, Schinzel AC, Singh S, Izzo F, Strickland MR, Luo L, Thomas SR, Boehm JS, Kim SY, Wang ZC and Hahn WC: PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene. 34:2061–2071. 2015. View Article : Google Scholar : PubMed/NCBI
10	Shiota M, Yokomizo A and Naito S: Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. Endocr Relat Cancer. 19:R243–R253. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yamato I, Sho M, Shimada K, Hotta K, Ueda Y, Yasuda S, Shigi N, Konishi N, Tsujikawa K and Nakajima Y: PCA-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis. Cancer Res. 72:4829–4839. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kanat O, O'Neil B and Shahda S: Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol. 7:401–410. 2015. View Article : Google Scholar : PubMed/NCBI
13	Ebell MH, Culp MB and Radke TJ: A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med. 50:384–394. 2016. View Article : Google Scholar : PubMed/NCBI
14	Mazzei MA, Guerrini S, Mazzei FG, Squitieri N Cioffi, Notaro D, de Donato G, Galzerano G, Sacco P, Setacci F, Volterrani L and Setacci C: Follow-up of endovascular aortic aneurysm repair: Preliminary validation of digital tomosynthesis and contrast enhanced ultrasound in detection of medium- to long-term complications. World J Radiol. 8:530–536. 2016. View Article : Google Scholar : PubMed/NCBI
15	Schalk SG, Demi L, Bouhouch N, Kuenen MPJ, Postema AW, de la Rosette JJMCH, Wijkstra H, Tjalkens TJ and Mischi M: Contrast-enhanced ultrasound angiogenesis imaging by mutual information analysis for prostate cancer localization. IEEE Trans Biomed Eng. 64:661–670. 2016. View Article : Google Scholar : PubMed/NCBI
16	Markic D, Krpina K, Ahel J, et al: Different presentations of renal cell cancer on ultrasound and computerized tomography. Urologia. 81:228–232. 2014. View Article : Google Scholar : PubMed/NCBI
17	Shi H, Wang Z, Huang C, Gu X, Jia T, Zhang A, Wu Z, Zhu L, Luo X, Zhao X, et al: A functional CT contrast agent for in vivo imaging of tumor hypoxia. Small. 12:3995–4006. 2016. View Article : Google Scholar : PubMed/NCBI
18	Krylova NS, Demkina AE, Poteshkina NG and Khashieva FM: Tissue Doppler imaging and ultrasonic methods for evaluating myocardial deformation in the diagnosis of hypertrophic cardiomyopathy. Kardiologiia. 54:79–84. 2014.(In Russian). View Article : Google Scholar : PubMed/NCBI
19	Chen CL, Hu GY, Mei Q, Qiu H, Long GX and Hu GQ: Epidermal growth factor receptor-targeted ultra-small superparamagnetic iron oxide particles for magnetic resonance molecular imaging of lung cancer cells in vitro. Chin Med J (Engl). 125:2322–2328. 2012.PubMed/NCBI
20	Shan L: Polyethylene glycol-coated and folic acid-conjugated superparamagnetic iron oxide nanoparticlesMolecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): 2004
21	Nakamoto Y, Ishimori T, Sano K, Temma T, Ueda M, Saji H and Togashi K: Clinical efficacy of dual-phase scanning using Ga-DOTATOC-PET/CT in the detection of neuroendocrine tumours. Clin Radiol. 71:1069.e1–5. 2016. View Article : Google Scholar
22	Angelov KG, Vasileva MB, Grozdev KS, Sokolov MB and Todorov G: Clinical and pathological characteristics, and prognostic factors for gastric cancer survival in 155 patients in Bulgaria. Hepatogastroenterology. 61:2421–2424. 2014.PubMed/NCBI
23	Dirani M, Nasreddine W, Abdulla F and Beydoun A: Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav Case Rep. 2:164–166. 2014. View Article : Google Scholar : PubMed/NCBI
24	Kargahi N, Razavi SM, Deyhimi P and Homayouni S: Comparative evaluation of eosinophils in normal mucosa, dysplastic mucosa and oral squamous cell carcinoma with hematoxylin-eosin, Congo red, and EMR1 immunohistochemical staining techniques. Electron Physician. 7:1019–1026. 2015.PubMed/NCBI
25	Soler M, Estevez MC, Villar-Vazquez R, Casal JI and Lechuga LM: Label-free nanoplasmonic sensing of tumor-associate autoantibodies for early diagnosis of colorectal cancer. Anal Chim Acta. 930:31–38. 2016. View Article : Google Scholar : PubMed/NCBI
26	Hopper AD and Campbell JA: Early diagnosis of oesophageal cancer improves outcomes. Practitioner. 260:23–28, 3. 2016.PubMed/NCBI
27	Shah RB, Leandro G, Romerocaces G, Bentley J, Yoon J, Mendrinos S, Tadros Y, Tian W and Lash R: Improvement of Diagnostic Agreement among Pathologists in Resolving an ‘Atypical Glands Suspicious for Cancer’ diagnosis in prostate biopsies utilizing a novel ‘Disease-Focused Diagnostic Review’ quality improvement process. Hum Pathol. 56:155–162. 2016. View Article : Google Scholar : PubMed/NCBI
28	Haider MA, Yao X, Loblaw A and Finelli A: Multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Systematic Review. Clin Oncol (R Coll Radiol). 28:550–567. 2016. View Article : Google Scholar : PubMed/NCBI
29	Chen WG, Yang CM, Xu LH, Zhang N, Liu XY, Ma YG, Huo XL, Han YS, Tian DA and Zheng Y: Gene chip technology used in the detection of HPV infection in esophageal cancer of Kazakh Chinese in Xinjiang Province. J Huazhong Univ Sci Technol Med Sci. 34:343–347. 2014. View Article : Google Scholar : PubMed/NCBI
30	Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B and Qiao YL: Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening. Zhonghua Yi Xue Za Zhi. 86:307–311. 2006.(In Chinese). PubMed/NCBI
31	Hampton T: Breast cancer gene chip study under way: Can new technology help predict treatment success? Jama. 291:2927–2930. 2004. View Article : Google Scholar : PubMed/NCBI
32	Watson RW: Gene-chip technology and prostate cancer: The identification of new genes regulating tumour progression. BJU Int. 91:3072003. View Article : Google Scholar : PubMed/NCBI
33	Kooiman J, Sijpkens YW, de Vries JP, Brulez HF, Hamming JF, van der Molen AJ, Aarts NJ, Cannegieter SC, Putter H, Swarts R, et al: A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography. Nephrol Dial Transplant. 29:1029–1036. 2014. View Article : Google Scholar : PubMed/NCBI
34	Mir MA, Bali BS, Mir RA and Wani H: Assessment of the severity of acute pancreatitis by contrast-enhanced computerized tomography in 350 patients. Ulus Travma Acil Cerrahi Derg. 19:103–108. 2013. View Article : Google Scholar : PubMed/NCBI
35	Kakimoto N, Chindasombatjaroen J, Tomita S, Shimamoto H, Uchiyama Y, Hasegawa Y, Kishino M, Murakami S and Furukawa S: Contrast-enhanced multidetector computerized tomography for odontogenic cysts and cystic-appearing tumors of the jaws: Is it useful? Oral Surg Oral Med Oral Pathol Oral Radiol. 115:104–113. 2013. View Article : Google Scholar : PubMed/NCBI
36	Freling N, Roele E, Schaefer-Prokop C and Fokkens W: Prediction of deep neck abscesses by contrast-enhanced computerized tomography in 76 clinically suspect consecutive patients. Laryngoscope. 119:1745–1752. 2009. View Article : Google Scholar : PubMed/NCBI
37	Konduru N, Keller J, Ma-Hock L, Gröters S, Landsiedel R, Donaghey TC, Brain JD, Wohlleben W and Molina RM: Biokinetics and effects of barium sulfate nanoparticles. Part Fibre Toxicol. 11:552014. View Article : Google Scholar : PubMed/NCBI
38	Liss P, Hansell P, Fasching A and Palm F: Iodinated contrast media inhibit oxygen consumption in freshly isolated proximal tubular cells from elderly humans and diabetic rats: Influence of nitric oxide. Ups J Med Sci. 121:12–16. 2016. View Article : Google Scholar : PubMed/NCBI
39	Mishra SK, Kumar BS, Khushu S, Tripathi RP and Gangenahalli G: Increased transverse relaxivity in ultrasmall superparamagnetic iron oxide nanoparticles used as MRI contrast agent for biomedical imaging. Contrast Media Mol Imaging. 11:350–361. 2016. View Article : Google Scholar : PubMed/NCBI
40	Kitoh Y: 5. Inspection of hepatocellular carcinoma 3-Contrast for the diagnosis of hepatocellular carcinoma: Techniques of image contrast and the choice of MR contrast agent. Nihon Hoshasen Gijutsu Gakkai Zasshi. 72:441–451. 2016.(In Japanese).
41	Zhang J, Liu J, Wang LM, Li ZY and Yuan Z: Retroreflective-type Janus microspheres as a novel contrast agent for enhanced optical coherence tomography. J Biophotonics. 10:878–886. 2017. View Article : Google Scholar : PubMed/NCBI
42	Rini BI and Atkins MB: Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
43	Eichelberg C, Junker K, Ljungberg B and Moch H: Diagnostic and prognostic molecular markers for renal cell carcinoma: A critical appraisal of the current state of research and clinical applicability. Eur Urol. 55:851–863. 2009. View Article : Google Scholar : PubMed/NCBI
44	Hutson TE: Targeted therapies for the treatment of metastatic renal cell carcinoma: Clinical evidence. Oncologist. 16 Suppl 2:S14–S22. 2011. View Article : Google Scholar
45	Pinto RP, Lima FK, Kulkzynski JM and Moreira LF: Expression of P16 and PDGFR-beta in gastric adenocarcinoma. Rev Col Bras Cir. 36:199–203. 2009.(In English, Portuguese). View Article : Google Scholar : PubMed/NCBI
46	Zhang F, Tang JM, Wang L, Wu PP and Zhang M: Immunohistochemical detection of RET proto-oncogene product in tumoral and nontumoral mucosae of gastric cancer. Anal Quant Cytopathol Histopathol. 36:128–136. 2014.
47	Bdo N Borges, Eda S Santos, Bastos CE, Pinto LC, Anselmo NP, Quaresma JA, Calcagno DQ, Burbano RM and Harada ML: Promoter polymorphisms and methylation of E-cadherin (CDH1) and KIT in gastric cancer patients from northern Brazil. Anticancer Res. 30:2225–2233. 2010.PubMed/NCBI
48	Kingston MJ, Perriman DM, Neeman T, Smith PN and Webb AL: Contrast agent comparison for three-dimensional micro-CT angiography: A cadaveric study. Contrast Media Mol Imaging. 11:319–324. 2016. View Article : Google Scholar : PubMed/NCBI
49	Lakin BA, Patel H, Holland C, Freedman JD, Shelofsky JS, Snyder BD, Stok KS and Grinstaff MW: Contrast-enhanced CT using a cationic contrast agent enables non-destructive assessment of the biochemical and biomechanical properties of mouse tibial plateau cartilage. J Orthop Res. 34:1130–1138. 2016. View Article : Google Scholar : PubMed/NCBI
50	Sudarski S, Henzler T and Schoenberg SO: Post-therapeutic positron emission tomography/computed tomography for early detection of non-small cell lung cancer recurrence. Transl Lung Cancer Res. 2:295–303. 2013.PubMed/NCBI
51	Hagberg GE, Mamedov I, Power A, Beyerlein M, Merkle H, Kiselev VG, Dhingra K, Kubìček V, Angelovski G and Logothetis NK: Diffusion properties of conventional and calcium-sensitive MRI contrast agents in the rat cerebral cortex. Contrast Media Mol Imaging. 9:71–82. 2014. View Article : Google Scholar : PubMed/NCBI
52	Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P and Roberts TP: Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging. 20:138–144. 2004. View Article : Google Scholar : PubMed/NCBI
53	Samei E, Saunders RS, Badea CT, Ghaghada KB, Hedlund LW, Qi Y, Yuan H, Bentley RC and Mukundan S Jr: Micro-CT imaging of breast tumors in rodents using a liposomal, nanoparticle contrast agent. Int J Nanomedicine. 4:277–282. 2009. View Article : Google Scholar : PubMed/NCBI